An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

AGN-241751 in the Treatment of Major Depressive Disorder

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Study of Rapastinel as Monotherapy in Patients With MDD

Randomized Trial of Adult Subjects With Generalized Anxiety Disorder

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

Escitalopram for Agitation in Alzheimer's Disease

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

AGN-241751 in the Treatment of Major Depressive Disorder

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks